Diverticulitis is the inflammation of the diverticulum which is a herniation of the mucosa and submucosa of the colonic wall that may fill with fecal material or undigested food particles.
Abdominal pain is usually localized, abrupt, steady and may worsen over time.
Other signs and symptoms are fever, anorexia, nausea without vomiting, and altered bowel movements, commonly constipation but may also present with diarrhea or tenesmus.
Noninclusion of antibiotics in the management of uncomplicated acute diverticulitis is feasible and fairly safe, with long-term follow-up data from the DIABOLO study showing that such a strategy does not result in increased incidence of complicated or recurrent diverticulitis or sigmoid resections over 2 years.
Recently, randomized controlled trials and guidelines have brought to light the benefits of extending the duration of H. pylori treatment. Below are summaries of guidelines and trials examining the regimens used to manage the infection.
At the recent Takeda Malaysia Vocinti® (vonoprazan) launch, held in conjunction with the Annual Scientific Meeting of the Malaysian Society of Gastroenterology and Hepatology - GUT 2019 at Shangri-La Kuala Lumpur, Professor Akihito spoke about vonoprazan’s merits as an alternative to conventional proton pump inhibitors.